Equitas Small Finance Bank IPO allotment: Here’s how to check share allotment status
Equitas Small Finance Bank
- The basis of allotment for ₹518 crore initial public offering of Equitas Small Finance Bank will be announced on October 27, and listing is scheduled for November 2.
- The Equitas, Small Finance Bank issue, was subscribed only 2 times on the last day of bidding.
- Here’s how to check Equitas Small Finance Bank IPO allotment status on registrar website and on stock-exchanges.
According to the stock-exchange data, the issue received bids for 22.57 crore equity shares against the offered size of 11.58 crore equity shares.
|Equitas Small Finance Bank IPO||Qualified Institutional Buyer||Non-institutional Investor||Retail Individual Investor||Employee||Others||Total|
|No. of times issue subscribed||3.91x||0.22x||2.08x||1.84x||0.42x||1.95x|
The basis of allotment for ₹518 crore initial public offering of Equitas Small Finance Bank will be announced on October 27, and listing is scheduled for November 2.
Here’s how to check Equitas Small Finance Bank IPO allotment status:
If you have bid for the Equitas Small Finance Bank IPO, you can check your allotment status by following these simple steps.
To check on the stock-exchange website:
- To check the Equitas Small Finance Bank IPO allotment status, go to the BSE website or NSE website.
- On BSE, Select ‘Equity’ and then from the dropdown, select ‘Equitas Small Finance Bank.’
- Now, enter your application number and PAN.
- Hit ‘Search’.
You can also visit the Registrar website (KFintech Private Limited) to check your application status.
- Since KFintech Private Limited is the registrar for Equitas Small Finance Bank IPO, you can visit their website here.
- Click on ‘Company selection’ and click on ‘Equitas Small Finance Bank -IPO.’ It will only appear post allotment on October 27.
- Once the company is selected, you will have to enter either your PAN detail, the application number, or client ID.
- Enter the captcha and click ‘submit.’
SEE ALSO: Trump calls India, China and Russia ‘filthy’ while justifying exit from Paris Agreement
Gilead's remdesivir just got the first FDA approval to be used as a treatment for coronavirus patients
Top stocks to watch — Cipla, Zydus Cadila, Dr Reddy Laboratories, Tech Mahindra, Avenue Supermarts, Cochin Shipyard, and others
- PM's visit to vaccine centres gets 'praise' from Congress
- Pollution, pandemic and pre-term birth
- Serum Institute of India threatens to seek ₹100 crore in damages from Chennai volunteer
- PM to interact with more teams of Covid-19 vaccine developers
- UP to have cold chain space for 1.23L litres of vaccine